{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:39:57Z","timestamp":1792435197729,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living with HIV (PLHIV) despite the availability of effective preventive interventions. Tuberculosis Preventive Therapy (TPT), strongly recommended by the World Health Organization, substantially reduces the risk of active TB among PLHIV, however, uptake of TPT remains suboptimal in many settings. This study, therefore, assessed the predictors of TPT initiation, beginning the course of anti-TB medications among PLHIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a health facility-based analytical cross-sectional study among 806 PLHIV aged\u2009\n                      <jats:italic>\u2265<\/jats:italic>\n                      \u200918 years attending antiretroviral therapy (ART) clinics in the Volta Region of Ghana. A systematic sampling technique was employed to recruit respondents, and data were collected using structured questionnaires mounted in the Kobo Toolbox. Data was exported to Stata version 17.0 for analysis. Descriptive and logistic regression analyses were performed, with statistical significance set at a\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 at 95% confidence interval.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our study found that out of the 806 PLHIV recruited, with a mean age of 44.7 years (SD\u2009\u00b1\u200913), the majority, 481 (59.70%), were found to have poor knowledge of TPT. We found that 620\/806 (88.6%) PLHIV were eligible for TPT, and among those eligible, only 236 (38.1%) were initiated on TPT. Respondents who had good knowledge of TPT were about 7 times more likely to be initiated compared with those who had poor knowledge (aOR\u2009=\u20096.79, 95% CI 4.69\u20139.83,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Those who had been diagnosed with HIV for one year or more were 4 times as likely to be initiated as those diagnosed for less than a year (aOR\u2009=\u20094.18, 95% CI 1.74\u201310.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Respondents in HIV clinical stage 2 were 66% less likely to be initiated than those in stage 1 (aOR\u2009=\u20090.34, 95% CI 0.20\u20130.58,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). With respect to marital status, married respondents were 40% less likely to be initiated on TPT compared with single respondents (aOR\u2009=\u20090.60, 95% CI 0.37\u20130.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038). Barriers perceived by PLHIV to TPT initiation were distance to facility, poor health education, and limited drug availability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TPT initiation among PLHIV in the Volta Region was suboptimal, and key predictors of initiation were TPT knowledge, duration since HIV diagnosis, HIV clinical stage, and marital status. Strengthening patient education, ensuring consistent drug and logistics availability, and addressing implementation barriers are critical to improving uptake and advancing progress toward Sustainable Development Goal 3.3 targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-026-28511-w","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:23:52Z","timestamp":1784773432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of tuberculosis preventive therapy initiation among people living with HIV in the Volta region, Ghana"],"prefix":"10.1186","volume":"26","author":[{"given":"Felix","family":"Mbiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raham Agbenorku Yaw","family":"Tawiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Berkumwin","family":"Der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"28511_CR1","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024."},{"issue":"9","key":"28511_CR2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/cid\/ciac185","volume":"75","author":"K Naidoo","year":"2022","unstructured":"Naidoo K, Moodley MC, Hassan-Moosa R, Dookie N, Yende-Zuma N, Perumal R, Dawood H, Mvelase NR, Mathema B, Karim SA. Recurrent subclinical tuberculosis among antiretroviral therapy\u2013accessing participants: incidence, clinical course, and outcomes. Clin Infect Dis. 2022;75(9):1628\u201336.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"28511_CR3","doi-asserted-by":"publisher","first-page":"e0223076","DOI":"10.1371\/journal.pone.0223076","volume":"14","author":"S Nyathi","year":"2019","unstructured":"Nyathi S, Dlodlo RA, Satyanarayana S, Takarinda KC, Tweya H, Hove S, Matambo R, Mandewo W, Nyathi K, Sibanda E, Harries AD. Isoniazid preventive therapy: uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS ONE. 2019;14(10):e0223076.","journal-title":"PLoS ONE"},{"key":"28511_CR4","volume-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240013131."},{"key":"28511_CR5","volume-title":"The End TB Strategy","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. The End TB Strategy. Geneva: World Health Organization; 2015. https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2015.19. WHO\/HTM\/TB\/2015.19."},{"issue":"11","key":"28511_CR6","doi-asserted-by":"publisher","first-page":"e0142290","DOI":"10.1371\/journal.pone.0142290","volume":"10","author":"HT Ayele","year":"2015","unstructured":"Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials. PLoS ONE. 2015;10(11):e0142290.","journal-title":"PLoS ONE"},{"issue":"11","key":"28511_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/09564624211014404","volume":"32","author":"M Takamiya","year":"2021","unstructured":"Takamiya M, Takarinda K, Balachandra S, Godfrey M, Radin E, Hakim A, Pearson ML, Choto R, Sandy C, Maphosa T, Rogers JH. Isoniazid preventive therapy use among adult people living with HIV in Zimbabwe. Int J STD AIDS. 2021;32(11):1020\u20137.","journal-title":"Int J STD AIDS"},{"key":"28511_CR8","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018","unstructured":"World Health Organization Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization; 2018. https:\/\/www.who.int\/publications\/i\/item\/9789241550239."},{"key":"28511_CR9","unstructured":"World Health Organization Global tuberculosis report. 2025. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data."},{"issue":"4","key":"28511_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5588\/pha.22.0030","volume":"12","author":"DP Baloyi","year":"2022","unstructured":"Baloyi DP, Anthony MG, Meyerson KA, Mazibuko S, Wademan D, Viljoen L, Myburgh H, Du Preez K, Osman M, Hirsch-Moverman Y, Charalambous S. Reasons for poor uptake of TB preventive therapy in South Africa. Public Health Action. 2022;12(4):159\u201364.","journal-title":"Public Health Action"},{"issue":"1","key":"28511_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s43058-023-00490-8","volume":"4","author":"BJ van de Water","year":"2023","unstructured":"van de Water BJ, Wilson M, le Roux K, Gaunt B, Gimbel S, Ware NC. Healthcare worker perceived barriers and facilitators to implementing a tuberculosis preventive therapy program in rural South Africa: a content analysis using the consolidated framework for implementation research. Implement Sci Commun. 2023;4(1):107.","journal-title":"Implement Sci Commun"},{"issue":"9596","key":"28511_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. lancet. 2007;370(9596):1453\u20137.","journal-title":"lancet"},{"key":"28511_CR13","unstructured":"Ghana Health Service. Consolidated guidelines for HIV care in Ghana: Test, Treat & Track. Accra: National AIDS\/STI Control Programme, Ghana Health Service; 2022. https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/Consolidated-Guidelines-For-Hiv-Care-In-Ghana.pdf."},{"key":"28511_CR14","doi-asserted-by":"publisher","unstructured":"Palacios CF, Moll AP, Shrestha R, Kompala T, Davis JL, Charalambous S et al Evaluating community knowledge of tuberculosis preventive therapy in rural South Africa. BMC Public Health. 2025;25(1):918. Available from: https:\/\/doi.org\/10.1186\/s12889-025-21719-2.","DOI":"10.1186\/s12889-025-21719-2"},{"key":"28511_CR15","doi-asserted-by":"publisher","unstructured":"Mindachew M, Deribew A, Tessema F, Biadgilign S Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC Public Health. 2011;11(1):916. Available from: https:\/\/doi.org\/10.1186\/1471-2458-11-916.","DOI":"10.1186\/1471-2458-11-916"},{"key":"28511_CR16","doi-asserted-by":"publisher","unstructured":"Roscoe C, Lockhart C, De Klerk M, Baughman A, Agolory S, Gawanab M et al Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis. BMC Public Health. 2020;20(1):1838. Available from: https:\/\/doi.org\/10.1186\/s12889-020-09902-z.","DOI":"10.1186\/s12889-020-09902-z"},{"key":"28511_CR17","first-page":"p12","volume-title":"WHO consolidated guidelines on tuberculosis: Module 1: Prevention-infection prevention and control","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: Module 1: Prevention-infection prevention and control. World Health Organization; 2022:p12."},{"key":"28511_CR18","unstructured":"World Health Organization, Global tuberculosis report; 2023. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2023."},{"issue":"11","key":"28511_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"28511_CR20","doi-asserted-by":"publisher","first-page":"e34156","DOI":"10.1371\/journal.pone.0034156","volume":"7","author":"A Gupta","year":"2012","unstructured":"Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS ONE. 2012;7(3):e34156.","journal-title":"PLoS ONE"},{"issue":"1","key":"28511_CR21","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1186\/1471-2458-11-916","volume":"11","author":"M Mindachew","year":"2011","unstructured":"Mindachew M, Deribew A, Tessema F, Biadgilign S. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC Public Health. 2011;11(1):916.","journal-title":"BMC Public Health"},{"key":"28511_CR22","first-page":"86","volume":"2","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Consolidated guidelines on tuberculosis. Module 1: Prevention. Tuberculosis preventive treatment. Tuberc Lung Dis HIV Infect. 2021;2:86\u201392. https:\/\/www.who.int\/publications\/i\/item\/9789240001503.","journal-title":"Tuberc Lung Dis HIV Infect"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-28511-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-28511-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-28511-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:02:50Z","timestamp":1792432970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-28511-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["28511"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-28511-w","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no personally identifiable data, including biomedical, clinical, and biometric data, images, or videos relating to people involved in this study, hence this is not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical issues: Ethical approval was sought from and granted by the University of Health and Allied Sciences Research Ethics Committee (UHAS-REC) with the clearance number UHAS-REC A.10[0]22\u201323). Permission to conduct this study and collect data was also obtained from the Hohoe Municipal Health Directorate and the Ketu South Municipal Health Directorate. All procedures involving human respondents were performed in accordance with the ethical standards of the UHAS-REC and in line with the principles of the Helsinki Declaration. Written informed consent was obtained from all respondents before their inclusion in the study. Participation was voluntary, and confidentiality and anonymity were ensured throughout the research process.Consent to Participate: Written informed consent was obtained from all respondents before their inclusion in the study. Respondents were informed about the purpose of the research, study procedures, potential risks and benefits, the voluntary nature of participation, and their right to withdraw at any time without any consequences. Confidentiality and anonymity were assured throughout the study, and no personal identifiers were included in the analysis or reporting of findings.","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"3000"}}